Effects and Complications of Intravesical Instillation of Bacillus Calmette-Guerin Therapy
- 6 Downloads
Purpose of Review
This review will address the current literature available regarding complications after intravesical Bacillus Calmette-Guerin (BCG) therapy for bladder cancer. Topics include intravesical BCG therapy–related complications, role of BCG therapy in immunosuppression, and future directions in the context of BCG-related complications.
There are several new reviews and case reports discussing unique complications following intravesical BCG therapy that should raise awareness of possible short-term and long-term effects after using this common treatment modality in bladder cancer patients.
Since intravesical BCG is a common treatment option for non-muscle invasive bladder cancer and can cause a variety of complications, it is important to recognize this aspect of the patient’s history when evaluating patients who present with symptoms similar to the ones discussed in this review. This will allow for prompt delivery of treatment as well as preventing unnecessary morbidity and mortality.
KeywordsIntravesical Bacillus Calmette-Guerin therapy BCG Non-muscle invasive bladder cancer Immunosuppression BCG complications
Acute kidney injury
Carcinoma in situ
Chronic kidney disease
Liver function tests
Lower urinary tract symptoms
Non-muscle invasive bladder cancer
Non-steroidal anti-inflammatory drugs
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 4.Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int. 2004;93(4):485–90. https://doi.org/10.1111/j.1464-410X.2003.04655.x.CrossRefGoogle Scholar
- 5.Pawinski A, Sylvester R, Kurth KH, Bouffioux C, van der Meijden A, Parmar MK et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. The J Urol 1996;156(6):1934–40, discussion 40-1.Google Scholar
- 6.Witjes JA, van der Meijden AP, Collette L, Sylvester R, Debruyne FM, van Aubel A, et al. Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacilli Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer. EORTCGU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group. Urology. 1998;52(3):403–10. https://doi.org/10.1016/S0090-4295(98)00212-X. CrossRefGoogle Scholar
- 9.Kamat AM, Flaig TW, Grossman HB, Konety B, Lamm D, O’Donnell MA, et al. Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat Rev Urol. 2015;12:225–35. https://doi.org/10.1038/nrurol.2015.58.
- 15.Jones JS, Larchian WA. Non-muscle-invasive bladder cancer (Ta, T1, CIS). In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh urology. Tenth ed. Philadelphia, PA: Elsevier Saunders; 2012.Google Scholar
- 16.• Lamm DL. Complications of bacillus Calmette-Guerin immunotherapy. Urol Clin North Am. 1992;19(3):565–72 Knowing when to give and when to withhold BCG will prevent most complications, but even when all precautions are taken, some complications will occur. This is a comprehensive and detailed landmark review of the literature of the diagnosis and management of different complications from BCG.Google Scholar
- 21.Macleod LC, Ngo TC, Gonzalgo ML. Complications of intravesical bacillus calmette-guerin. Can Urol Assoc J 2014:8(7–8):e540–4. Doi: https://doi.org/10.5489/cuaj.1411, 540, E544.
- 22.Bilsen MP, van Meijgaarden KE, de Jong HK, Joosten SA, Prins C, Kroft LJM, et al. A novel view on the pathogenesis of complications after intravesical BCG for bladder cancer. Int J Infect Dis. 2018;72:63–8. https://doi.org/10.1016/j.ijid.2018.05.006.
- 23.Gonzalez OY, Musher DM, Brar I, Furgeson S, Boktour MR, Septimus EJ, et al. Spectrum of Bacille Calmette-Guerin (BCG) infection after intravesical BCG immunotherapy. Clin Infect Dis. 2003;36:140–8. https://doi.org/10.1086/344908.
- 25.Hoag N, Pommerville PJ, Kibsey PC, Cavers DJ, Eddy RJ. Tuberculous epididymitis following intravesical Bacillus Calmette-Guerin immunotherapy. Can J Urol. 2009;16(2):4589–91.Google Scholar
- 29.Elzein F, Albogami N, Saad M, Tayeb NE, Alghamdi A, Elyamany G. Disseminated Mycobacterium bovis infection complicating intravesical BCG instillation for the treatment of superficial transitional cell carcinoma of the bladder. Clin Med Insights: Case Rep. 2016;9:71–3. https://doi.org/10.4137/CCRep.S39904.Google Scholar
- 30.Colombel M, Saint F, Chopin D, Malavaud B, Nicolas L, Rischmann P, et al. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol. 2006;176:935–9. https://doi.org/10.1016/j.juro.2006.04.104.
- 32.Samadian S, Phillips FM, Deeab D. Mycobacterium bovis vertebral osteomyelitis and discitis with adjacent mycotic abdominal aortic aneurysm caused by intravesical BCG therapy: a case report in an elderly gentleman. Age Ageing. 2013;42:129–31. https://doi.org/10.1093/ageing/afs164.CrossRefGoogle Scholar
- 33.Kusakabe T, Endo K, Nakamura I, Suzuki H, Nishimura H, Fukushima S, et al. Bacille calmette-guerin (BCG) spondylitis with adjacent mycotic aortic aneurysm after intravesical BCG therapy: a case report and literature review. BMC Infect Dis. 2018;18(1):290. https://doi.org/10.1186/s12879-018-3205-7.
- 35.Gao CQ, Mithani R, Leya J, Dawravoo L, Bhatia A, Antoine J, et al. Granulomatous hepatitis, choroiditis and aortoduodenal fistula complicating intravesical Bacillus Calmette-Guerin therapy: case report. BMC Infect Dis. 2011;11:260. https://doi.org/10.1186/1471-2334-11-260.
- 36.Davis FM, Miller DJ, Newton D, Arya S, Escobar GA. Successful treatment of a mycotic multifocal thoracoabdominal aortic aneurysm as a late sequelae of intravesical bacillus calmette-guerin therapy: case report and literature review. Ann Vasc Surg. 2015;29:840.e9–e13. https://doi.org/10.1016/j.avsg.2014.12.020.CrossRefGoogle Scholar
- 37.Ziegler J, Ho J, Gibson IW, Nayak JG, Stein M, Walkty A, et al. Disseminated Mycobacterium bovis infection post-kidney transplant following remote intravesical BCG therapy for bladder cancer. Transpl Infect Dis. 2018;20:e12931. https://doi.org/10.1111/tid.12931.